Why Is REPLIGEN CORP (RGEN) Stock Moving Today?

RGEN stock surged 6.63% to $188.06 in intraday trade, driven by positive developments tied to Moderna’s Phase 3 trial for melanoma therapy. The biotech sector experienced renewed momentum as analysts highlighted potential benefits for Repligen from the trial results. The stock opened with a 1.4% gap up and reached a session high of $188.73 before settling near $188.46.

What Happened

Repligen’s stock price climbed following analyst commentary that positioned the company as a key beneficiary of Moderna’s recent clinical trial data. Stifel and Wells Fargo both cited the potential for Repligen to gain from the progress in cancer vaccine development. Additionally, price targets from Wells Fargo and J.P. Morgan were raised, with Wells Fargo setting a target of $185 and J.P. Morgan at $175. These adjustments came amid broader biotech sector optimism, with Amgen also reporting strong Q2 results. The stock’s move reflects investor anticipation of continued momentum from favorable developments in the oncology space.

What The Data Shows

The stock’s intraday performance showed a volatile session, with a low of $173.13 and a high of $188.73. Trading volume reached 0.5 million shares, which is 0.4 times the 3-month daily average. The stock hit a fresh 52-week high on August 20, 2026. Over the past 30 days, sentiment has improved, rising from an average of 62 to 68. Recent insider transactions included two sales by the CFO, totaling $186,000. No insider purchases were reported in the last 90 days.

What To Watch

Investors should monitor the company’s next earnings report if scheduled. Otherwise, continued analyst coverage and broader market sentiment toward biotech stocks will be key factors to watch.